51˶

Lawmakers Push for MDMA Approval; Dogs and Depression; Barriers to OUD Prescribing

— News and commentary from the psychiatry world

MedpageToday
Illustration of a brain shaped maze.

A bipartisan group of House and Senate lawmakers is to approve Lykos Therapeutics' midomafetamine (MDMA)-assisted treatment for post-traumatic stress disorder; an FDA decision is expected in the coming days. (The Hill)

Among adults with schizophrenia receiving paliperidone palmitate (Invega Hafyera) every 6 months, for up to 3 years. (JAMA Network Open)

GLP-1 receptor agonists for weight-loss like anorexia in certain patients, doctors warned. (NBC News)

A strong bond with pets, especially dogs, was linked with for middle-age and older women. (JAMA Network Open)

Among mental health patients in the U.K. who died by suicide, a case-controlled study revealed that was more common among those with autism, prior psychological treatment, or a history of childhood abuse. (Lancet Regional Health Europe)

Repetitive transcranial magnetic stimulation was more effective in than switching antidepressants in people with moderately treatment-resistant depression. (American Journal of Psychiatry)

Twenty-one states had a ratio of less than one per 5,000 births in 2022; South Dakota, Montana, and Mississippi had the lowest density. (JAMA Network Open)

Thinking can be unpleasant for some people, suggested. (Psychological Bulletin)

Training requirements may not be the primary barrier to for opioid use disorder (OUD), according to a cross-sectional study of four states. (JAMA Network Open)

One psychiatrist suggested people think twice for someone in a mental health crisis. (PLOS Mental Health)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.